Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Clinical Trials Related to Olaparib
Related studies linked through entity extraction aliases.
Study of Pamiparib in Newly Diagnosed and rGBM
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
- Status
- TERMINATED
- Phase
- PHASE2
Anlotinib Combined With Dose-reduced Olaparib in Patients With Platinum-Sensitive Recurrent Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Olaparib Real-world Utilization and Clinical Outcomes in France, Italy, and the UK
- Status
- COMPLETED
- Phase
- N/A
Olaparib in Patients With HRD Malignant Mesothelioma
- Status
- RECRUITING
- Phase
- PHASE2
Pembrolizumab and Olaparib in Cervical Cancer Patients
- Status
- TERMINATED
- Phase
- PHASE2
Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)
- Status
- COMPLETED
- Phase
- PHASE3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Olaparib With Ceralasertib in Recurrent Osteosarcoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Delayed Initiation of Olaparib Maintenance Therapy in Platinum Sensitive Recurrent Ovarian Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
- Status
- TERMINATED
- Phase
- PHASE2
Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE4